Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
The company's leaders promised to keep their own shares locked up until early 2027, meaning they can't sell them. This shows confidence in the company's future, since leaders usually only lock up shares when they believe the business will do well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.